timothy sykes logo

Stock News

Is Sangamo Therapeutics Stock Ready to Surge After Exciting FDA News?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Is Sangamo Therapeutics Stock Ready to Surge After Exciting FDA News? Thumbnail

Sangamo Therapeutics Inc. is likely seeing a positive price movement due to its promising collaboration efforts and potential breakthroughs in gene therapy. On Friday, Sangamo Therapeutics Inc.’s stocks have been trading up by 7.33 percent.

Key Developments for Sangamo Therapeutics

  • The FDA has granted clearance for Sangamo’s new investigational drug ST-503, designed to treat idiopathic small fiber neuropathy, pushing the stock up by 11%.

Candlestick Chart

Live Update At 11:37:11 EST: On Friday, December 13, 2024 Sangamo Therapeutics Inc. stock [NASDAQ: SGMO] is trending up by 7.33%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • Following the FDA decision, Barclays has increased its price target on Sangamo from $3 to $9, maintaining an Overweight rating due to optimistic Fabry program outcomes.

  • Sangamo’s stock rose sharply as it achieved FDA clearance for ST-503, a potential game-changer in neuropathic pain treatment, addressing significant unmet medical needs.

Sangamo Therapeutics’ Earnings Insight

In trading, the key to success is not just about earning large sums, but managing it wisely. As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This insight highlights the importance of strategic thinking and disciplined management in trading. Many traders get caught up in the excitement of gains, but it’s the preservation and smart utilization of those earnings that truly determine long-term success in the trading world.

Sangamo Therapeutics Inc. revealed its recent financial performance, pointing to some intriguing figures. Revenues reached approximately $176M, which shows a notable increase in terms of cash inflows. Employing a down-to-earth tone, let’s clarify what these numbers mean. Though boasting a gross margin of 100%, Sangamo’s EBIT margin was at -260%, bespeaking cost challenges. Their pretax profit margin and total profit margins also depict a rough landscape with figures somewhat steeped in red.

With total expenses seated at around $39M, the company’s ability to manage costs efficiently was laid bare. Even though debt to equity stands at a modest 0.71, Sangamo remains agile with a current ratio of 1.4. Cash flows from operating activities were aligned nearly at $11.8M, reflecting continued operational reshaping. Despite carrying forward losses in some lines, they charted changes in their financial reporting to better reflect ongoing scene changes. Sangamo has made decisions that couple innovation with sustainable business practice which is intriguing for future prospects.

More Breaking News

In the financial sphere, such improvements alongside challenging metrics trigger an engaging debate. The broader spectrum shows Sangamo’s endeavors in innovation as its nexus for future profitability. The recent FDA clearance catalyzes anticipation, bolstering momentum and morale but must be met with cost-tightening strategies to carve sustainable growth fully.

Unpacking the Impactful Announcements

Recent announcements crafted pivotal moments for Sangamo Therapeutics, with ripples touching Stock Market waters far and wide. It’s exciting how the FDA’s clearance of ST-503 became a blockbuster catalyst, scouting Sangamo as a trailblazer in neuropathy treatment. This approval confirmed Sangamo’s expertise in tackling niche medical needs, ceasing whispers about efficacy and placing them at the frontier of genetic therapies.

In a literal climb, Sangamo’s stock rallied thanks to the administrative green light from FDA, and how you might ask? Investors understood it strengthens pipe dreams into a formidable fact. The closure brought a conviction that pivots financially—highlighting sections of Fabry and ZFP transcription factor neurology avenues.

Barclays showed similar optimism, significantly upping their price proclamation by pushing targets to $9. Perhaps, it was a courtesy nod to Sangamo sailing smoothly amid rough R&D storms. Such positive attention wasn’t idle, shaping market buyer sentiment to buzz reminiscent of early biotech heroics. Essentially, elements in SGMO’s strategic chess became worth a broader market gaze, leaving us to conjecture about Sangamo’s unfolding chapters with earnesty.

Conclusion: Navigating the Sangamo Odyssey

Sangamo’s surge post-FDA nod offers a moment of repose mixed with intrigue. For the weary who have watched from the sidelines, embracing this march must echo careful optimism when shaded by past financial struggles. As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Balancing promise seen in ST-503 against prevailing financial metrics may provide rights reserved for agile traders. The scene post-update chalks an artful composition, vividly inviting participants at the stock exchange to either leap or cautiously pause on Sangamo’s next big move.

While appearances put Sangamo Therapeutics in a narrative of resilience, its true destiny hangs on continuing efficacy and economic viability. Engaged eyes may also ponder broader industry undercurrents as Sangamo’s arc shapes, inspiring and cautionary in equal measure for those willing to take the adventurous plunge.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Our traders will never trade any stock until they see a setup they like. Their strategy is to capture short-term momentum while avoiding undue risk exposure to a stock’s long-term volatility. This method is especially useful when trading penny stocks or other high-risk equities, where rapid gains can be made by understanding stock patterns, manipulation, and media hype. Whether you are an active day trader looking for key indicators on a stock’s next move, or an investor doing due diligence before entering a position, Timothy Sykes News is designed to help you make informed trading decisions.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade, the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”